


O-Desmethyl gefitinib-d₈

Cat. No.:	HY-100064S		
Molecular Formula:	C ₂₁ H ₁₄ D ₈ ClFN ₄ O ₃		
Molecular Weight:	440.93		
Target:	EGFR		
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (226.79 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.2679 mL	11.3397 mL	22.6793 mL	
5 mM	0.4536 mL	2.2679 mL	4.5359 mL	
10 mM	0.2268 mL	1.1340 mL	2.2679 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

O-Desmethyl gefitinib-d₈ is a deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits EGFR with an IC₅₀ of 36 nM in subcellular assays[1][2].

IC₅₀ & Target

IC₅₀: 36 nM (EGFR)^[2]

REFERENCES

[1]. Kobayashi H, et al. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. *Med Oncol.* 2016 Jun;33(6):57.

[2]. McKillop D, et al. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. *Xenobiotica.* 2006 Jan;36(1):29-39.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA